Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) is a biotechnology company focused on developing and commercializing therapeutics for rare genetic disorders of appetite regulation. The company is known for its work on treatments targeting hypothalamic obesity and rare metabolic conditions involving the regulation of hunger and energy balance.
Company News
Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results.
Rhythm Pharmaceuticals reported strong Q1 2025 results, with $37.7 million in net product revenue from IMCIVREE and positive data from its pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The company also provided updates on its pipeline and anticipated upcoming milestones.
Rhythm Pharmaceuticals' financial health appears stable, with a sufficient cash runway extended by recent funding. See why RYTM stock is a Hold.
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The biotech could pursue these two budget-friendly targets.